AQST Live signals | Maximize Profits with Getagraph.com

SELL 103019 min ago

@ $2.70

Issued: 14 Feb 2024 @ 09:30

Return: 45.56%

Previous signal: Feb 12 - 12:17

Previous signal: Buy

Return: -2.17 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	1.91M
Average Volume	2.54M
Market Cap	353.57M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-0.0900 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-30.23
ATR14	$0.00900 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Schobel Alexander Mark	Sell	50 000	Common Stock
2024-03-09	Barber Daniel	Sell	37 938	Common Stock
2024-03-09	Boyd Peter E.	Sell	8 370	Common Stock
2024-03-09	Braender Lori J	Sell	10 530	Common Stock
2024-03-09	Toth A Ernest Jr	Sell	11 705	Common Stock

INSIDER POWER
89.76
Last 98 transactions
Buy: 6 570 786 \| Sell: 225 172

Volume Correlation

Long: -0.03 (neutral)

Short: 0.23 (neutral)

Signal:(51.665) Neutral

Aquestive Therapeutics Correlation

10 Most Positive Correlations
ATRS	0.946
MDLZ	0.94
MMSI	0.939
CWST	0.938
ISEE	0.938
XLRN	0.937
HAPP	0.935
MTRY	0.93
CFIV	0.928
OSIS	0.928

10 Most Negative Correlations
OBT	-0.951
HONE	-0.948
GBNY	-0.946
FRAF	-0.943
PFC	-0.943
WNEB	-0.942
AUB	-0.941
COFS	-0.941
EVBG	-0.94
PNBK	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aquestive Therapeutics Correlation - Currency/Commodity

-0.27
( neutral )

-0.41
( neutral )

0.00
( neutral )

0.20
( neutral )

Aquestive Therapeutics Financials

Annual	2023
Revenue:	$50.58M
Gross Profit:	$29.97M (59.25 %)
EPS:	$-0.130

Q4	2023
Revenue:	$13.21M
Gross Profit:	$8.53M (64.57 %)
EPS:	$-0.120

Q3	2023
Revenue:	$13.00M
Gross Profit:	$8.20M (63.10 %)
EPS:	$-0.0315

Q2	2023
Revenue:	$13.24M
Gross Profit:	$6.62M (50.03 %)
EPS:	$-0.100

Financial Reports:

No articles found.

Aquestive Therapeutics

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.